Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tigris Pharmaceuticals has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug, AFP-464 for the treatment of cancer. The first patient was dosed in December 2007 and enrollment is ongoing.
Subscribe to our email newsletter
The primary objectives of the study are to determine the dose-limiting toxicity and maximum tolerated dose of AFP-464 in patients with advanced solid tumors. The trial is expected to enroll up to approximately 35 patients across two sites in Europe. Results from the trial are expected to be available in early 2009.
Edmundo Muniz, CEO of Tigris, said: “AFP-464 is a first-in-class molecule with the potential to fill a large unmet medical need in the treatment of cancer. This first trial in Europe along with the two US Phase I trials provides us our first opportunity to assess the drug’s activity in patients, and to further build on our understanding of the molecule’s mechanism of action.”